second remission was referred for BMT. After conditioning with fractionated total body irradiation of 13.2 Gy and cyclophosphamide 120 mg/kg body weight, she received a Ocular flutter is a rare neurologic condition occurring in patients suffering from viral encephalitis, intramarrow allograft from a phenotypically matched unrelated donor. For CNS prophylaxis, methotrexate (MTX) at a dose cranial neoplasia, paraneoplastic syndrome or intoxications. Neurotoxicity is a recognized complication of of 12 mg was given intrathecally once prior to bone marrow infusion. For prophylaxis of GVHD, CsA and intravenous cyclosporin A (CsA) therapy, but ocular flutter has not been reported in association with CsA administration MTX were given according to the Seattle protocol. The patient recovered without serious complications and was to date. We describe a 17-year-old female patient who developed ocular flutter 51 days after transplantation discharged 25 days after transplantation. No signs of acute GVHD were observed and prophylactic immunosuppreswith marrow from an unrelated donor, for acute myeloid leukemia. After discontinuation of cyclosporin, sion with oral CsA adjusted to serum levels of around 200 ng/ml was maintained. Antiviral prophylaxis and Pneumowhich was given for prophylaxis of graft-versus-host disease, the clinical symptoms resolved within 3 weeks, cystis carinii prophylaxis were given (famcyclovir 500 mg twice a day, cotrimoxazole 4 tablets/week). Due to poor but a slightly abnormal electrooculogram persisted for more than 10 months.

